证券代码：688765 证券简称：禾元生物 公告编号：2025-004 武汉禾元生物科技股份有限公司 关于购买董高责任险的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步完善武汉禾元生物科技股份有限公司（以下简称"公司"）风险管 理体系，降低公司运营风险，保障公司及公司董事和高级管理人员的权益和广大 投资者利益，促进公司管理层充分行使权利、履行职责，根据《上市公司治理准 则》等相关规定，公司拟为公司及全体董事和高级管理人员购买责任险（以下简 称"董高责任险"）。 （三）赔偿限额：不超过人民币 10,000 万元（具体以保险合同为准）； （四）保费支出：不超过人民币 40 万元/年（具体以保险合同为准）； （五）保险期限：12 个月（后续每年可续保或重新投保）。 公司于2025年11月21日召开第四届董事会第十一次会议，审议了《关于购买 董高责任险的议案》，因公司董事均为被保险对象，作为利益相关方，全体董事 在审议该事项时回避表决，直接提交公司股东会审议。现将有关事项公告如下： 一、董高责任险具体方案： （一） ...

证券代码：688765 证券简称：禾元生物 公告编号：2025-005 （一） 股东会类型和届次 2025年第三次临时股东会 召开日期时间：2025 年 12 月 12 日 15 点 00 分 召开地点：武汉市东湖新技术开发区神墩五路 268 号禾元生物 10 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 武汉禾元生物科技股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 12 日 至2025 年 12 月 12 日 无 二、 会议审议事项 本次股东会审议议案及投票股东类型 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 股东会召开日期：2025年12月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网 ...

武汉禾元生物科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688765 证券简称：禾元生物 武汉禾元生物科技股份有限公司 2025 年第三次临时股东会 会议资料 | 2025 | 年第三次临时股东会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第三次临时股东会会议议程 | 4 | | 2025 | 年第三次临时股东会会议议案 | 6 | | | 议案一： | 6 | 武汉禾元生物科技股份有限公司 2025 年第三次临时股东会会议资料 武汉禾元生物科技股份有限公司 2025 年第三次临时股东会会议须知 为维护全体股东的合法权益，确保武汉禾元生物科技股份有限公司（以下简 称"禾元生物"或"公司"）股东会正常秩序和议事效率，根据《中华人民共和 国公司法》《中华人民共和国证券法》等法律法规及《武汉禾元生物科技股份有 限公司章程》和公司《股东会议事规则》的相关规定，制定以下会议须知，请出 席股东会的全体人员遵守执行。 一、会议期间，全体出席人员应以维护股东的合法权益、保证股东会的正常 秩序和议事效率为原则，认真履行法定义务，自觉遵守股东会纪律，不得侵犯其 他股东的 ...

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Group 1 - The core point of the news is that He Yuan Bio experienced a decline in stock price by 3.29% on November 17, with a trading volume of 531 million yuan [1][2] - On the same day, He Yuan Bio had a financing buy-in amount of 54.18 million yuan and a net financing buy-in of 6.57 million yuan, with a total financing and securities balance of 375 million yuan as of November 17 [1][2] - The company reported a significant increase in the number of shareholders, reaching 47,100, which is an increase of 84,075% compared to the previous period [2] Group 2 - He Yuan Bio's main business involves the research, production, and sales of products using rice endosperm cell recombinant protein expression technology, with recombinant human albumin accounting for 75.44% of its revenue [2] - For the period from January to September 2025, He Yuan Bio achieved a revenue of 19.66 million yuan, representing a year-on-year decrease of 8.51%, while the net profit attributable to the parent company was -121 million yuan, also a decrease of 8.44% year-on-year [2]

Group 1 - The restructuring protein concept declined by 1.71%, ranking among the top declines in the concept sector, with notable declines in stocks such as Kexing Pharmaceutical, Haoyuan Pharmaceutical, and Zejing Pharmaceutical [1] - Among the stocks in the restructuring protein concept, 8 stocks saw price increases, with *ST Wanfang, ST Weiming, and Lideman leading with increases of 4.96%, 2.21%, and 1.76% respectively [1] - The restructuring protein concept experienced a net outflow of 742 million yuan from main funds today, with 38 stocks seeing net outflows, and 8 stocks with outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock in the restructuring protein concept was Heyuan Biological, with a net outflow of 82.99 million yuan, followed by Sangfor Guojian, Zhifei Biological, and Zhongyuan Xiehe with net outflows of 59.97 million yuan, 57.83 million yuan, and 56.32 million yuan respectively [2][3] - The stocks with the highest net inflow included *ST Wanfang, Furuida, and Yinuote, with net inflows of 10.67 million yuan, 8.92 million yuan, and 7.75 million yuan respectively [4]

Group 1 - The company has not yet established any collaboration with He Yuan Biotechnology Co., Ltd [2] - The company focuses on the blood products sector and is committed to technology-driven product development [2] - The company maintains an open attitude towards new technologies and closely monitors market dynamics and industry advancements to enhance its overall competitive strength [2]

Core Viewpoint - He Yuan Bio's stock price has experienced a decline of 4.23% year-to-date and 8.12% over the last five trading days, with significant trading activity noted in recent sessions [1][2]. Group 1: Stock Performance - On November 14, He Yuan Bio's stock rose by 2.06%, reaching 87.25 CNY per share, with a trading volume of 95.86 million CNY and a turnover rate of 2.69% [1]. - Year-to-date, He Yuan Bio's stock has dropped by 4.23%, and it has fallen by 8.12% in the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, reflecting a year-on-year decrease of 8.51% [2]. - The company's net profit attributable to shareholders was -121 million CNY, a decline of 8.44% year-on-year [2]. Group 3: Company Overview - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1].

Market Performance - The Sci-Tech Innovation Board (STAR Market) index fell by 0.58%, closing at 1379.45 points, with a total trading volume of 4.193 billion shares and a turnover of 181.687 billion yuan, resulting in an average turnover rate of 2.19% [1] - Among the tradable stocks on the STAR Market, 188 stocks closed higher, with 3 stocks rising over 10% and 9 stocks rising between 5% and 10%. Conversely, 396 stocks closed lower, with 7 stocks declining over 10% [1] Turnover Rate Analysis - The turnover rate distribution shows that 3 stocks had a turnover rate exceeding 20%, 14 stocks had a turnover rate between 10% and 20%, and 45 stocks had a turnover rate between 5% and 10% [1] - The highest turnover rate was recorded by Magu Technology at 30.12%, closing up by 5.39%, with a transaction amount of 670 million yuan. He Yuan Biological followed with a turnover rate of 27.54%, closing up by 2.90%, with a transaction amount of 990 million yuan [1][3] Stock Performance - In terms of stock performance, among the stocks with a turnover rate exceeding 5%, 27 stocks rose today, with the highest increases seen in Dekoli (up 11.93%), Ruikeda (up 11.00%), and Yingfang Software (up 8.61%). Conversely, the largest declines were in Artis (down 14.33%), Lais Information (down 12.20%), and World (down 11.12%) [2] - The electronic industry had the most stocks with a turnover rate exceeding 5%, totaling 18 stocks, followed by the power equipment and pharmaceutical sectors with 14 and 9 stocks, respectively [2] Capital Flow - Among the high turnover stocks, 30 stocks experienced net inflows of main funds, with the largest inflows in Shijia Photon (188 million yuan), Baijishenzhou (178 million yuan), and Dekoli (151 million yuan). In contrast, Tianhe Energy, Jinpan Technology, and Artis saw the largest net outflows, totaling 445 million yuan, 180 million yuan, and 163 million yuan, respectively [2] - Recent leverage fund movements indicate that 46 stocks received net purchases of leveraged funds, with the largest increases in financing balances for Artis (552 million yuan), Purun Shares (289 million yuan), and Jinpan Technology (267 million yuan). Conversely, the largest decreases were seen in Jiehuate, Foxit Software, and Xinxiangwei, with reductions of 183 million yuan, 177 million yuan, and 166 million yuan, respectively [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has experienced a significant decline in stock price and financial performance, with a notable drop in trading activity and net outflow of funds [1][2]. Group 2 - As of November 12, He Yuan Bio's stock price increased by 2.33% to 88.00 CNY per share, with a trading volume of 1.16 billion CNY and a market capitalization of 31.46 billion CNY [1]. - The company has seen a net outflow of 11.32 million CNY in principal funds, with large orders showing a buy of 20.27 million CNY and a sell of 27.88 million CNY [1]. - Year-to-date, He Yuan Bio's stock price has decreased by 3.40%, and it has dropped 21.43% over the last five trading days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on November 7, where it recorded a net buy of -69.68 million CNY [1]. Group 3 - He Yuan Bio, established on November 16, 2006, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of products using rice endosperm cell recombinant protein expression technology [1]. - The company's main business revenue composition includes 75.44% from recombinant human albumin and 24.56% from other products [1]. Group 4 - He Yuan Bio belongs to the pharmaceutical and biological industry, specifically in the blood products sector, and is associated with concepts such as innovative drugs, newly listed stocks, biopharmaceuticals, and mid-cap stocks [2]. - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2]. - For the period from January to September 2025, He Yuan Bio reported a revenue of 19.66 million CNY, a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million CNY, also down 8.44% year-on-year [2].